XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss $ (2,940,897) $ (3,282,227)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation – G&A 54,670 50,804
Depreciation – cost of revenue 48,305 36,328
Amortization of intangible asset 42,742
Amortization and interest expense of operating lease assets 1,054,794 989,003
Depreciation of right-of-use finance assets 17,200 15,480
Provision of allowance for expected credit loss on accounts receivable 82,151 1,956
Provision of allowance for expected credit loss on loan receivable 288,000
Amortization of discount and bond issuance cost 98,835
Deferred tax expense (23,494) 89,581
Interest income (100,052)
Stock-based compensation expense for consulting services 940,860
Changes in operating assets and liabilities:    
Accounts receivable – third parties (932,852) 424,648
Accounts receivable – related parties (47,610) 565,766
Note receivables 65,152
Contract assets 50,142 98,118
Inventories, net (27,802) (10,328)
Right of return asset 70,169
Other receivable – related parties (143,789) (241,702)
Prepayment, deposit and other receivable (2,856,298) (112,620)
Accounts payables – third parties 404,825 28,285
Accounts payables – related parties 135,197 (156,165)
Contract liabilities 35,428
Accrued expense and other payables 389,301 312,722
Refund liabilities 71,761
Tax payable 94,806
Operating lease liabilities (1,341,522) (742,649)
Net cash used in operating activities (4,469,978) (1,933,000)
Cash flows from investing activities:    
Purchase of furniture and equipment (36,072)
Payment for leasehold improvement (75,008)
Net cash payment for asset acquisition (552,721)
Loan to a third party (7,037,190) (686,697)
Loan to a related party (108,800)
Net cash used in investing activities (7,145,990) (1,350,498)
Cash flows from financing activities:    
Proceeds from loans 1,644,523 195,000
Repayment of loans (597,546) (339,914)
Repayment of principal of convertible debts (399,615)
Repayment of equipment and vehicle loans (40,666) (55,877)
Principal payment of finance lease liabilities (16,290) (14,964)
Advances from Hupan Pharmaceutical prior to acquisition 276,365
Proceeds from initial public offering, net of share issuance costs 5,351,281
Proceeds from a private placement 7,133,492
Advances to related parties (62,779) (311,185)
Proceeds from related party 260,144
Proceeds from shareholders 174,626
Repayment to shareholders (805,345)
Net cash provided by financing activities 8,095,889 4,295,361
Effect of exchange rate changes on cash 205,457 (11,999)
Net (decrease) increase in cash (3,314,622) 999,864
Cash, beginning of the period 4,956,060 123,550
Cash, end of the period 1,641,438 1,123,414
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:    
Cash paid for income tax 17,043
Cash paid for interest 354,942 45,953
NON-CASH ACTIVITIES    
Right of use assets obtained in exchange for operating lease obligations 1,445,498
Right of use assets obtained in exchange for finance lease obligation 89,003
SUPPLEMENTAL SCHEDULE OF NON-CASH IN INVESTING AND FINANCING ACTIVITIES    
Additions to property and equipment included in loan payable 69,544 102,235
Additions to leasehold improvement and furniture and fixture through account payable 42,803
Settlement of due to shareholder and advance to related party 311,185
Convertible notes converted to common shares 512,733
Issuance of common shares in exchange for consulting service $ 4,422,700